We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our
Privacy Policy
Profacgen offers ADCC Assay Services, providing quantitative, reproducible evaluation of antibody-dependent cellular cytotoxicity, enabling precise characterization of Fc-mediated NK cell killing across therapeutic antibody development workflows.
Antibody-dependent cellular cytotoxicity (ADCC) is a critical Fc effector mechanism in which the Fc region of an antibody bound to a target cell engages FcγRIIIa (CD16a) on natural killer (NK) cells, triggering directed release of cytotoxic granules and target cell apoptosis. The ability to measure ADCC with physiological relevance, statistical rigor, and platform flexibility directly supports lead candidate selection, Fc engineering optimization, biosimilar comparability, and regulatory potency testing.
Overview of ADCC
Figure 1. ADCC mechanism: antibody binding to target cell, recruitment of NK cells, FcγRIIIa engagement, and directed target cell killing. (Hendrikset al., 2017)
ADCC proceeds through a sequential, receptor-mediated cascade that links antigen recognition on target cells to innate immune cytotoxicity:
Target Cell: Antigen-expressing target cells are identified and bound by the Fab region of the therapeutic antibody
Antibody Binding: Bivalent antibody engagement stabilizes attachment to the target cell surface, positioning the Fc region for immune recognition
NK Cell Recruitment: Circulating or assay-derived NK cells are recruited to the antibody-coated target through chemotactic and contact-dependent mechanisms
FcγRIIIa Engagement: The Fc region binds to FcγRIIIa (CD16a) on the NK cell surface, triggering ITAM-mediated intracellular signaling
Target Cell Killing: Activated NK cells release perforin, granzymes, and cytotoxic cytokines, inducing apoptosis of the bound target cell
Quantitative assessment of each step—and of the integrated cascade—enables mechanistic understanding, potency determination, and comparability evaluation across antibody candidates and manufacturing lots.
Our ADCC Assay Platforms
Profacgen provides multiple ADCC assay platforms to accommodate diverse antibody formats, target cell types, and program requirements. Platform selection is guided by desired physiological relevance, throughput, reproducibility, and regulatory context.
Primary NK Cell ADCC Assays
Physiologically relevant evaluation using donor-derived primary NK cells as effector populations.
Fresh and cryopreserved NK cell isolation and qualification
Target cell killing quantification by flow cytometry, LDH release, or viability dyes
Ideal for mechanism-of-action studies and Fc engineering evaluation
PBMC-Based ADCC Assays
Mixed immune effector population assessment reflecting closer-to-in vivo immune complexity.
Peripheral blood mononuclear cell preparation and effector cell enrichment
Natural NK cell proportion within mixed lymphocyte populations
Assessment of ADCC in the context of competing Fcγ receptor interactions
Suitable for early-stage screening and immunological context evaluation
Engineered Effector Cell Assays
High reproducibility and throughput using stable effector cell lines engineered for ADCC measurement.
ADCC reporter effector cells with NFAT-driven luciferase expression
Defined FcγRIIIa expression levels for consistent effector-to-target ratios
Minimized donor variability and assay drift across batches
Optimized for potency testing, lot release, and comparability studies
Reporter Gene ADCC Assays
Direct FcγRIIIa activation readout for quantitative potency assessment and high-throughput screening.
Luciferase or fluorescent reporter systems linked to FcγRIIIa signaling pathways
Dose-response quantification with EC50 and EMAX determination
Compatible with 96-well and 384-well formats for screening campaigns
Recommended for potency testing and biosimilar comparability
Assay Readouts
Profacgen supports multiple quantitative readouts to capture distinct aspects of ADCC biology, enabling comprehensive characterization aligned with program objectives:
Target Cell Lysis: Direct quantification of target cell death using viability dyes, LDH release, or flow cytometry-based apoptosis markers
Reporter Activity: Luminescence or fluorescence measurements reflecting FcγRIIIa signaling pathway activation in engineered effector cells
Cytokine Release: Multiplex quantification of IFN-γ, TNF-α, and other NK cell-derived cytokines using ELISA
Effector Cell Activation: Flow cytometry assessment of CD107a degranulation, intracellular perforin/granzyme B expression, and activation marker upregulation
EC50 Determination: Dose-response curve fitting and potency parameter calculation using nonlinear regression and statistical modeling
Figure 2. Technical readouts of ADCC. (Vincken et al., 2025)
Fc Engineering Evaluation
Profacgen's ADCC assays support comprehensive evaluation of Fc-engineered antibody variants designed to modulate effector function:
Fc Variant Screening: Comparative ADCC assessment of amino acid substitutions (e.g., S239D/I332E, GASDALIE) designed to enhance or reduce FcγRIIIa binding
Glycoengineering Assessment: Evaluation of afucosylated, bisecting, or other glycoform variants for enhanced ADCC potency through improved FcγRIIIa affinity
FcγR Binding Correlation: Parallel measurement of FcγRIIIa, FcγRIIa, and FcγRIIb binding to correlate biophysical properties with functional ADCC outcomes
Applications
Our ADCC assays support a broad spectrum of applications across therapeutic antibody development and characterization:
Lead Candidate Selection: Quantitative comparison of ADCC potency across candidate panels to inform lead selection and ranking decisions
Antibody Optimization: Iterative refinement of antibody candidates based on structure-ADCC relationships and Fc engineering data
Biosimilar Comparability: Rigorous side-by-side assessment to demonstrate functional equivalence between innovator and biosimilar products
Lot Release Support: Routine potency testing and stability assessment for manufacturing lot release and in-process control
Potency Testing: GLP-compliant assay execution for regulatory submission and clinical batch qualification
Deliverables
Profacgen provides structured, decision-ready documentation aligned with your program's analytical and regulatory requirements:
Dose-response curves: Complete concentration-response relationships with replicate data and curve fitting parameters
EC50 values: Relative potency metrics with 95% confidence intervals and statistical significance assessment
Maximum response (EMAX): Efficacy ceiling determination for comparative and absolute potency evaluation
Statistical analysis: Appropriate modeling (4-parameter logistic, sigmoidal dose-response) with goodness-of-fit metrics and outlier evaluation
Study report: Comprehensive documentation of assay methods, raw data, analyzed results, and interpretative summaries suitable for regulatory review or internal decision-making
A therapeutic antibody development program required quantitative ADCC data to guide Fc engineering decisions aimed at enhancing NK cell-mediated killing for an oncology indication. Multiple Fc variants with altered glycosylation and amino acid substitutions needed functional comparison against a wild-type benchmark.
Objective:
To generate reproducible, statistically robust ADCC potency data across Fc variant candidates using physiologically relevant primary NK cell and high-throughput reporter assays, enabling data-driven selection of an optimized lead.
Approach:
Profacgen implemented a tiered ADCC evaluation strategy: primary NK cell assays for mechanistic relevance and reporter gene assays for high-throughput screening. Dose-response curves were generated for each variant, with EC50 and EMAX values compared using appropriate statistical models. FcγRIIIa binding affinity was measured in parallel to correlate biophysical properties with functional outcomes.
Outcome:
The program identified an afucosylated variant with significantly enhanced ADCC potency relative to wild-type, supported by consistent data across both assay platforms. The structured dataset enabled confident progression to downstream development and regulatory discussion.
A biosimilar development program required rigorous demonstration of functional equivalence between a candidate product and the reference innovator antibody, with ADCC potency being a critical quality attribute for regulatory approval.
Objective:
To execute a statistically powered ADCC comparability study demonstrating that the biosimilar candidate falls within the predefined equivalence margin relative to the reference product, using validated assay platforms and qualified reagents.
Approach:
Profacgen conducted side-by-side ADCC assays using qualified engineered effector cells and multiple target cell lines. Assay qualification included precision, linearity, and robustness evaluation. Multiple independent runs were performed with appropriate statistical analysis to assess equivalence using confidence interval approaches.
Outcome:
The biosimilar candidate demonstrated ADCC potency within the predefined equivalence margin across all assay conditions and statistical analyses. The comprehensive dataset and structured report supported regulatory submission and accelerated the path to clinical development.
Q: What is ADCC and why is it important for therapeutic antibodies?
A: ADCC (Antibody-Dependent Cellular Cytotoxicity) is an Fc-mediated immune mechanism in which NK cells kill antibody-coated target cells through FcγRIIIa engagement. It is a critical effector function for many therapeutic antibodies, particularly in oncology, where direct tumor cell killing contributes to clinical efficacy.
Q: Which ADCC assay platform is most appropriate for my program?
A: Platform selection depends on your program stage and objectives. Primary NK cell assays offer physiological relevance for mechanism-of-action studies. Reporter gene and engineered effector cell assays provide high reproducibility and throughput for potency testing, lot release, and biosimilar comparability. PBMC-based assays reflect in vivo immune complexity for early screening.
Q: How does Fc engineering affect ADCC potency?
A: Fc engineering can enhance or reduce ADCC through multiple mechanisms. Amino acid substitutions (e.g., S239D/I332E) increase FcγRIIIa affinity. Glycoengineering (e.g., afucosylation) improves FcγRIIIa binding by modifying the Fc glycan structure. Conversely, certain mutations can silence Fc effector function when cell killing is undesirable.
Q: What is the difference between ADCC and CDC assays?
A: ADCC involves immune cell-mediated killing through Fcγ receptor engagement on NK cells or macrophages. CDC involves complement-mediated target cell lysis initiated by C1q binding to the Fc region and activation of the classical complement cascade. Both are Fc effector functions but operate through distinct molecular and cellular mechanisms.
Q: Can ADCC assays support regulatory submissions?
A: Yes. Profacgen can execute ADCC assays under method qualification or validation protocols aligned with ICH guidelines and regulatory expectations. Structured documentation, statistical analysis, and assay performance characterization support IND-enabling studies, BLA submissions, and biosimilar comparability packages.
Q: How is assay variability controlled across donor sources?
A: For primary NK cell and PBMC assays, we implement donor qualification criteria, FcγRIIIa allotype characterization, and internal reference standards to monitor assay performance. Engineered effector cell assays eliminate donor variability entirely, providing consistent performance across studies and timepoints.
References:
Vincken R, Armendáriz-Martínez U, Ruiz-Sáenz A. ADCC: the rock band led by therapeutic antibodies, tumor and immune cells. Front Immunol. 2025;16:1548292. doi:10.3389/fimmu.2025.1548292
Antibody-based cancer therapy. In: International Review of Cell and Molecular Biology. Vol 331. Elsevier; 2017:289-383. doi:10.1016/bs.ircmb.2016.10.002
Online Inquiry
Fill out this form and one of our experts will respond to you within one business day.
Figure 1. ADCC mechanism: antibody binding to target cell, recruitment of NK cells, FcγRIIIa engagement, and directed target cell killing. (Hendrikset al., 2017)
Figure 2. Technical readouts of ADCC. (Vincken et al., 2025)